Tumor-associated peptides binding to human leukocyte antigen (HLA) class II molecules

• US 10,196,432 B2
• Filed: 09/05/2006
• Issued: 02/05/2019
• Est. Priority Date: 09/05/2005
• Status: Active Grant

• Current Assignee: Immatics Biotechnologies GmbH (Immatics NV)
• Original Assignee: Immatics Biotechnologies GmbH (Immatics NV)
• Inventors: Dengiel, Jorn
• Primary Examiner(s): Bredefeld, Rachael E
• Assistant Examiner(s): Dabkowski, Erinne R
• Application Number:
  US11/912,670
• Publication Number:
  US 20100040590A1
• Time in Patent Office: 4,536 Days
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C07K 14/7051 T-cell receptor (TcR)-CD3 complex

Abstract

The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.

Claims

1. A composition comprising an isolated tumor associated peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NO:

2 to SEQ ID NO;

29, SEQ ID NO;

31, SEQ ID NO;

32, and SEQ ID NO;

34 to SEQ ID NO;

48, a pharmaceutically acceptable carrier, and at least one immune-stimulating adjuvant, wherein the immune-stimulating adjuvant is selected from the group consisting of incomplete Freund'"'"'s adjuvant, complete Freund'"'"'s adjuvant, liposomal formulations, Bacillus Calmette-Gudrin (BCG), alum, Detox, CpG oligonucleotides, Interleukin-12 (IL-12), Interleukin-2 (IL-2) and stabilized RNA and wherein the peptide is produced by solid phase peptide synthesis and cleaved from a resin support by treatment with trifluoroacetic acid.

2. The composition according to claim 1, wherein the peptide has the ability to bind human major histocompatibility complex (MHC) class-II molecule HLA-DRB*0101 and has the ability to bind to at least one additional molecule of the human major histocompatibility complex (MHC) class-II.

3. The composition of claim 1, wherein the composition further comprises at least one excipient selected from a buffer, a binding agent, a blasting agent, a diluent, a flavour and a lubricant.

4. A fusion protein consisting of a tumour associated peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NO:

2 to SEQ ID NO;

29, SEQ ID NO;

31, SEQ ID NO;

32, and SEQ ID NO;

34 to SEQ ID NO;

48 and the 80 N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).